New weight loss pill beats oral Ozempic in major trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Orforglipron, a once-daily pill developed by Eli Lilly, outperformed oral semaglutide in a 52-week Phase 3 trial of 1,698 adults with type 2 diabetes across six countries.
- Orforglipron cut HbA1c by 1.71–1.91% versus 1.47% for oral semaglutide, and produced average weight loss of 6.1–8.2 kg compared with 5.3 kg on semaglutide.
- Roughly 59% of orforglipron users reported gastrointestinal side effects (nausea, vomiting, diarrhea, or constipation), versus 37–45% on oral semaglutide.
- About 10% of orforglipron participants discontinued treatment due to adverse effects, compared with 4–5% on oral semaglutide.
- As a synthetic small-molecule drug, orforglipron is cheaper to manufacture than peptide-based semaglutide and requires no refrigeration, removing cold-chain barriers for low- and middle-income countries.
- No head-to-head trial has compared orforglipron with injectable GLP-1s such as Ozempic or Wegovy; trials in patients with obesity but without diabetes are still ongoing.
Why it matters: Orforglipron's small-molecule design — synthetic, refrigerator-free, cheaper to produce than peptide drugs like semaglutide — removes cold-chain barriers that have constrained GLP-1 access in low- and middle-income countries. But with 10% of users discontinuing due to side effects versus 4–5% on oral semaglutide, tolerability is the line separating the two products in a crowded weight-loss market.
